Reprogrammed Stem Cells Emerge as Potent Next-Gen Cancer Vaccines

Dendritic cell (DC)-based cancer vaccines have long held theoretical promise but face steep practical barriers: DCs are difficult and expensive to isolate and expand, produce variable patient responses, and express PD-L1, which can paradoxically suppress the very T-cell responses vaccines aim to generate. Only one DC-based therapy—Sipuleucel-T (Provenge®) for prostate cancer—has reached FDA approval, with modest clinical benefit. This review argues that mesenchymal stromal cells (MSCs) represent a transformative alternative platform for cancer vaccination.

MSCs are non-hematopoietic progenitor cells found in bone marrow, adipose tissue, menstrual blood, and other sources. They adhere readily to plastic, expand robustly in culture, and exhibit remarkable immunoplasticity—shifting between immunosuppressive and pro-inflammatory phenotypes depending on environmental cues. In their native state, MSCs lack MHC-II (HLA-DR), CD80, and CD86, making them invisible to adaptive immunity. However, interferon-gamma (IFNγ) stimulation can briefly confer antigen-presenting capacity. This early finding was ultimately limited because the antigen-presenting window is narrow and the treated cells co-express PD-L1, risking immune suppression in vivo.

To overcome these limitations, researchers pursued two major reprogramming strategies. Genetically, MSCs were engineered to stably express the immunoproteasome (IPr) complex—normally found in immune cells—producing 'IRMs.' These cells exhibit upregulated MHC-I, CD80, and IL-12 production, and activate HIF-1α signaling, enabling potent cross-presentation of tumor antigens without IFNγ dependence. A related variant, 'TRMs,' expresses the thymoproteasome (TPr) complex, normally exclusive to cortical thymic epithelial cells, and adds unique peptide repertoire generation capabilities. Both IRMs and TRMs demonstrated effective tumor control in multiple murine cancer models in prophylactic and therapeutic settings.

Pharmacological reprogramming offers a non-genetic alternative. Certain small molecules and stressors—including those inducing reactive oxygen species (ROS) and endoplasmic reticulum (ER) stress—can naturally drive MSCs toward an APC-like phenotype. This mechanistic insight suggests that cellular stress pathways are upstream regulators of MSC immunoplasticity, opening doors for off-the-shelf pharmacological priming protocols that avoid genetic modification entirely.

The review situates these advances within a broader MSC clinical landscape that now includes FDA-approved Ryoncil® (2024) for acute graft-versus-host disease, as well as approved products for osteoarthritis, Crohn's fistula, ALS, and myocardial infarction. The authors argue that MSC-APCs combine the manufacturing scalability of MSCs with the immunostimulatory power needed for effective cancer vaccination. Key open questions remain: the full surface phenotype of MSC-APCs, optimal antigen-loading strategies, and whether efficacy in murine models will translate to human tumors.